Search
Search
About
Log in
Join
Experiences with
Lymphocytic leukemia
Posts
Communities
3,080 public posts
Filter results
Webinar - Oral Therapies and Adherence in Lymphoma and CLL Jan 23 2020, 2:00-3:00 PM EST
Register at: https://beacon360.content.online/xbcs/S1791/catalog/product.xhtml?eid=16215
Register at: https://beacon360.content.online/xbcs/S1791/catalog/product.xhtml?eid=16215
wmay13241
in
CLL Support
5 years ago
PJP prophylaxis may be unnecessary for CLL patients on BTK inhibitors
From a report from the recent Edinburgh iWCLL 2019, [i]"Routine empiric prophylaxis against pneumocystis jiroveci pneumonia (PJP) may be unwarranted in chronic
lymphocytic
leukemia
patients initiating Bruton tyrosine kinase (BTK) inhibitor therapy, a retrospective chart review suggests."[/i] Dr.
From a report from the recent Edinburgh iWCLL 2019, [i]"Routine empiric prophylaxis against pneumocystis jiroveci pneumonia (PJP) may be unwarranted in chronic
lymphocytic
leukemia
patients initiating Bruton tyrosine kinase (BTK) inhibitor therapy, a retrospective chart review suggests."[/i] Dr.
AussieNeil
Partner
in
CLL Support
5 years ago
ASH 2019: A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma
"Conclusion : This study demonstrates that it is safe to administrate a single dose of Sativex to elderly patients with indolent B-cell lymphoma with regards to adverse events. We show that the cannabis compound quickly reduces lymphoma cell numbers in peripheral blood. There was no evidence of activation
"Conclusion : This study demonstrates that it is safe to administrate a single dose of Sativex to elderly patients with indolent B-cell lymphoma with regards to adverse events. We show that the cannabis compound quickly reduces lymphoma cell numbers in peripheral blood. There was no evidence of activation
avzuclav
in
CLL Support
5 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
One-to-one buddy support
One of our buddies, was featured in this week's Telegraph along with his match. you can read more here, part of the Telegraph Christmas appeal https://telegraph.co.uk/christmas/2019/11/14/cancer-buddies-sometimes-another-person-leukaemia-understands/ Earlier this year, we had a chat about why be a
One of our buddies, was featured in this week's Telegraph along with his match. you can read more here, part of the Telegraph Christmas appeal https://telegraph.co.uk/christmas/2019/11/14/cancer-buddies-sometimes-another-person-leukaemia-understands/ Earlier this year, we had a chat about why be a
HAIRBEAR_UK
Administrator
in
Leukaemia CARE
5 years ago
Hens teeth, aggressive sarcomatoid sccs and ruxolitinib
Hi. I’ve just been informed that that the sarcomatoid scc that I’d had excised from my cheek on Nov 6 th was indeed a recurrence of the same type that I’d had before, and it has a poor prognosis. Radiotherapy on my face might help prevent more spreading. Or might not. The new lesion was described
Hi. I’ve just been informed that that the sarcomatoid scc that I’d had excised from my cheek on Nov 6 th was indeed a recurrence of the same type that I’d had before, and it has a poor prognosis. Radiotherapy on my face might help prevent more spreading. Or might not. The new lesion was described
Rachelthepotter
in
MPN Voice
5 years ago
New member
Hi, im Angie, i was diagnosed with CML in October 2016. Ive been on imatinib 400mg since diagnosis and the main side effect being chronic fatigue. Just recently the fatigue has gotten worse and the consultant said its nothing to do the meds or illness. Got to say its really getting down now, i go swimming
Hi, im Angie, i was diagnosed with CML in October 2016. Ive been on imatinib 400mg since diagnosis and the main side effect being chronic fatigue. Just recently the fatigue has gotten worse and the consultant said its nothing to do the meds or illness. Got to say its really getting down now, i go swimming
Swimmer19
in
Leukaemia CARE
5 years ago
MF review article : Treatment options 2019
Hi. This is a very clear summary of treatment options. Just google MF and Ruxolitinib , and the article summary comes up. You can also print off a PDF of the whole article, if you are lucky. Worth showing to your haematologist. Myelofibrosis in 2019: moving beyond JAK2 inhibition” Schieber et al. Blood
Hi. This is a very clear summary of treatment options. Just google MF and Ruxolitinib , and the article summary comes up. You can also print off a PDF of the whole article, if you are lucky. Worth showing to your haematologist. Myelofibrosis in 2019: moving beyond JAK2 inhibition” Schieber et al. Blood
Rachelthepotter
in
MPN Voice
5 years ago
iwCLL 2019 | Five-year follow up of the UK CLL Forum ibrutinib data
Dr Toby Eyre, MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the UK chronic
lymphocytic
leukemia
(CLL) forum study led by George Follows, Cambridge University Hospitals, Cambridge, UK, and the 5-year follow up data for ibrutinib in R/R CLL.
Dr Toby Eyre, MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the UK chronic
lymphocytic
leukemia
(CLL) forum study led by George Follows, Cambridge University Hospitals, Cambridge, UK, and the 5-year follow up data for ibrutinib in R/R CLL.
Jm954
Administrator
in
CLL Support
5 years ago
WEIGHT GAINS WITH JAKAFI
Post by MPN-MATE Admin » Sat Nov 23, 2019 9:53 pm Hey guys... :D As someone who is taking Ruxolitinib, I found this paper's frank admissions rather interesting seeing that the funding is coming from the manufacturers of Ruxolitinib (Jakafi). It is definitely worth a good read, as it explains how
Post by MPN-MATE Admin » Sat Nov 23, 2019 9:53 pm Hey guys... :D As someone who is taking Ruxolitinib, I found this paper's frank admissions rather interesting seeing that the funding is coming from the manufacturers of Ruxolitinib (Jakafi). It is definitely worth a good read, as it explains how
socrates_8
in
MPN Voice
5 years ago
CLL Society Support Group Meetings USA Coming Up!
CLL Society Support Group Meetings Coming Up! https://myemail.constantcontact.com/CLL-Society-Alert----December-3--2019.html?soid=1120967015548&aid=3A0RRuM8V-s https://cllsociety.org/events/ - San Diego CLL Society Support and Education Meeting - December 4 @ 4:00 pm - New Orleans and Surrounding
CLL Society Support Group Meetings Coming Up! https://myemail.constantcontact.com/CLL-Society-Alert----December-3--2019.html?soid=1120967015548&aid=3A0RRuM8V-s https://cllsociety.org/events/ - San Diego CLL Society Support and Education Meeting - December 4 @ 4:00 pm - New Orleans and Surrounding
lankisterguy
Volunteer
in
CLL Support
5 years ago
Test Before Treat
Test Before Treat™ Although this comes from the USA, the logic and reasoning can apply to any international patient and medical professionals. https://cllsociety.org/wp-content/uploads/2019/08/Test-Before-Treat-One-pager-V3.pdf "More Patients Spill the Beans on their Test Before Treat™ Experiences
Test Before Treat™ Although this comes from the USA, the logic and reasoning can apply to any international patient and medical professionals. https://cllsociety.org/wp-content/uploads/2019/08/Test-Before-Treat-One-pager-V3.pdf "More Patients Spill the Beans on their Test Before Treat™ Experiences
lankisterguy
Volunteer
in
CLL Support
5 years ago
Potential Early Drivers of Disease in Treatment-Naive CLL Identified
[/i] By determining the relationship between a set of somatic mutations and established prognostic clinical features with time-to-first treatment (TTFT), study researchers identified potential early drivers of disease among treatment-naive chronic
lymphocytic
leukemia
(TN CLL) patients.
[/i] By determining the relationship between a set of somatic mutations and established prognostic clinical features with time-to-first treatment (TTFT), study researchers identified potential early drivers of disease among treatment-naive chronic
lymphocytic
leukemia
(TN CLL) patients.
Jm954
Administrator
in
CLL Support
5 years ago
Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease.
December 8, 2019 ASH poster. There are lots of us on long term Ibrutinib who have had a good response but still have a small amount of residual disease. I would welcome the chance to add venetoclax to my treatment as in this study which is an important piece of work by Michael J Keating et al. "[i]Patients
December 8, 2019 ASH poster. There are lots of us on long term Ibrutinib who have had a good response but still have a small amount of residual disease. I would welcome the chance to add venetoclax to my treatment as in this study which is an important piece of work by Michael J Keating et al. "[i]Patients
Jm954
Administrator
in
CLL Support
5 years ago
Transformation Confirmed - Likely Richter’s
My doctor called yesterday and confirmed my PET from last week shows definite transformation and the PA called today to say it’s likely Richter’s (forgot to ask if confirmed by the biopsy - still shock) and they want to start treatment this week. I’m headed back to Houston for consult and planning.
My doctor called yesterday and confirmed my PET from last week shows definite transformation and the PA called today to say it’s likely Richter’s (forgot to ask if confirmed by the biopsy - still shock) and they want to start treatment this week. I’m headed back to Houston for consult and planning.
SarasotaPaul
in
CLL Support
5 years ago
Does taking Nplate causes nose bleed ?
I'm currently in week 3 of taking Nplate. It could boost my platelet count to 32 however I have nosebleed sometimes recently. I was wondering if it's a side effect of NPlate or something serious?
I'm currently in week 3 of taking Nplate. It could boost my platelet count to 32 however I have nosebleed sometimes recently. I was wondering if it's a side effect of NPlate or something serious?
farasad2001
in
ITP Support Association
5 years ago
Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL
Reducing or interrupting duvelisib (Copiktra) treatment does not increase toxicity or reduce outcomes with relapsed/refractory chronic
lymphocytic
leukemia
/small
lymphocytic
lymphoma (CLL/SLL).
Reducing or interrupting duvelisib (Copiktra) treatment does not increase toxicity or reduce outcomes with relapsed/refractory chronic
lymphocytic
leukemia
/small
lymphocytic
lymphoma (CLL/SLL).
Jm954
Administrator
in
CLL Support
5 years ago
Long time DX,SORT TIME TMT
I was diagnosed with CLL in 1995. I’ve been on W&W until this year in Sept. at age 86. Treatment was initiated Ibrutinib 140mg, orally per diem. I’ve positive movement with my numbers and the splenomegaly. My nodes were minimally involved. My side effects have been undetectable. Given good response
I was diagnosed with CLL in 1995. I’ve been on W&W until this year in Sept. at age 86. Treatment was initiated Ibrutinib 140mg, orally per diem. I’ve positive movement with my numbers and the splenomegaly. My nodes were minimally involved. My side effects have been undetectable. Given good response
desti
in
CLL Support
5 years ago
No fear and so grateful for Mutation diagnoses
So for the past eight years since starting treatment for ET I was in chronic all over skeletal pain also neurological (all from medication as I had NO pain before). I now have Myelofibrosis and to be honest am over the moon!! Instead of it being a negative it’s like I have a life worth living again.
So for the past eight years since starting treatment for ET I was in chronic all over skeletal pain also neurological (all from medication as I had NO pain before). I now have Myelofibrosis and to be honest am over the moon!! Instead of it being a negative it’s like I have a life worth living again.
StreetPastor
in
MPN Voice
5 years ago
Dr Michael Keating's Story - Taking CLL Therapies From Bedside to Community
A fascinating overview of one of the giants in CLL research, who provided many of us with the first treatment capable of prolonging life expectancy (FCR) and for about 60% of those who are mutated IgHV, effectively a cure. From humble beginnings in Melbourne Australia, to a fulfilling career at the
A fascinating overview of one of the giants in CLL research, who provided many of us with the first treatment capable of prolonging life expectancy (FCR) and for about 60% of those who are mutated IgHV, effectively a cure. From humble beginnings in Melbourne Australia, to a fulfilling career at the
AussieNeil
Partner
in
CLL Support
5 years ago
IVGH results
Hello. I am new to the group, just diagnosed this month. My last CBC showed absolute lymphocytes at 5280. I was feeling pretty good after my doctor explained what CLL is, how it progresses etc. But today I got results of another test back with the following: IVGH Borderline Mutated Mutation Rate 3.0
Hello. I am new to the group, just diagnosed this month. My last CBC showed absolute lymphocytes at 5280. I was feeling pretty good after my doctor explained what CLL is, how it progresses etc. But today I got results of another test back with the following: IVGH Borderline Mutated Mutation Rate 3.0
lmav
in
CLL Support
5 years ago
1
...
69
70
71
...
100
Next page
30
40
50
60
70
80
90
100
Filter results
Clear filters
Posted in
All communities
CLL Support
1933 results
MPN Voice
786 results
Leukaemia CARE
168 results
View top 10 communities
Sort by
Most Relevant
Newest